|
| T cell functions | Increased
IgM-specific T cell suppressor function [35, 40, 41];
normal T cell suppression function [42–44] |
| Excessive
isotype nonspecific T cell suppressive activity [40]; increased IgM specific
suppressive T cell function [35] |
| Defect
in T cell help [10, 26];
normal
T cell help [17, 42, 44, 45] |
| Nonspecific T cell abnormalities [26];
normal
T cell function [42] |
|
| B cell
function | Defect
in B cell differentiation into IgM-immunoglobulin secreting cells [40, 46, 47] |
|
| T and B cell enumeration and
phenotype | Normal
peripheral T and B cell phenotypes [42, 43, 47, 48];
increased
CD8+ cells and inverted CD4/CD8 ratios [40];
increased
CD4+ cells and decreased CD8+ cells [47] |
| Reduced
number of IgM secreting B cells [45, 46] with a failure of secreted mu mRNA
synthesis [46];
normal
surface IgM expression on B cells [10, 17, 35, 43, 47–49]; normal
secreted mu mRNA synthesis [49] |
|
| Mitogen/antigen stimulation | Mitogen
and antigen stimulated B cell proliferation assays with normal IgM responses
[11, 42];
decreased
antigen proliferation IgM responses [4, 17, 40, 41, 45–49] |
| Deficient
IgM responses to viral antigens and/or endotoxin containing vaccines and
deficient isohemagglutinin antibodies [24] |
| Failure
to respond to antigen challenge with tetanus toxoid, pneumococcal
vaccine, meningococcus vaccine, Salmonella O and H antigens, and
typhus-paratyphus vaccine [10–12, 19, 42, 50] |
|
| Complement | No
complement deficits [10] |
|
| Delayed hypersensitivity | Reduced
delayed cutaneous hypersensitivity [10, 17];
normal
delayed cutaneous hypersensitivity [11, 42] |
|
| Phagocytosis | Normal
phagocytosis and killing of encapsulated bacteria [10]; nominally affected opsonification of yeast
particles [11];
select opsonic defect against Pseudomonas [51] |
|
